VELA Investment Management LLC Buys 2,089 Shares of Agilent Technologies, Inc. (NYSE:A)

VELA Investment Management LLC increased its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 147.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,508 shares of the medical research company’s stock after buying an additional 2,089 shares during the quarter. VELA Investment Management LLC’s holdings in Agilent Technologies were worth $455,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Agilent Technologies by 18.2% during the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after buying an additional 4,605,228 shares in the last quarter. Norges Bank bought a new stake in Agilent Technologies during the fourth quarter worth $509,904,000. Massachusetts Financial Services Co. MA lifted its holdings in Agilent Technologies by 19.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 13,246,489 shares of the medical research company’s stock worth $1,841,659,000 after acquiring an additional 2,170,219 shares during the period. Brown Advisory Inc. boosted its position in Agilent Technologies by 262.1% in the fourth quarter. Brown Advisory Inc. now owns 2,292,929 shares of the medical research company’s stock worth $318,786,000 after purchasing an additional 1,659,768 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Agilent Technologies by 13.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock valued at $1,242,956,000 after purchasing an additional 1,042,926 shares during the last quarter. 87.42% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the transaction, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, SVP Dominique Grau sold 15,000 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at $3,497,110. The disclosure for this sale can be found here. Insiders sold 18,916 shares of company stock worth $2,557,230 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Agilent Technologies Stock Up 0.1 %

Shares of NYSE A opened at $138.34 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The company has a market cap of $40.36 billion, a P/E ratio of 32.70, a P/E/G ratio of 6.63 and a beta of 1.05. Agilent Technologies, Inc. has a 52 week low of $96.80 and a 52 week high of $155.35. The business has a 50-day simple moving average of $135.47 and a two-hundred day simple moving average of $139.01.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. Agilent Technologies’s revenue was down 5.6% compared to the same quarter last year. During the same period last year, the business earned $1.43 earnings per share. Research analysts anticipate that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A has been the topic of a number of research analyst reports. TD Cowen boosted their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. UBS Group boosted their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. JPMorgan Chase & Co. decreased their price target on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $135.00 price target (down previously from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd. Finally, Evercore ISI increased their price objective on Agilent Technologies from $130.00 to $135.00 and gave the company an “in-line” rating in a report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $141.60.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.